S

Sartorius

Bioprocess and laboratory solutions provider

Business Process Expert - Operations & Supply Chain Management

Full-TimeUpdated on 10/23/2026
No salary listed
Mid
Bachelor's
Yauco, Puerto Rico
In PersonOn-site workplace in Yauco, Puerto Rico.
Business & StrategyBusiness Operations

About the job

Requirements
  • An academic degree in Business Administration, Industrial Engineering, Supply Chain Management, Information Management, Business Analytics, or a related field is required.
  • Significant experience in business process management, process optimization, operational excellence, or continuous improvement roles within a manufacturing environment is required.
  • Strong understanding of end-to-end business processes, with deep expertise in Manufacturing and solid knowledge of Supply Chain and Procurement processes, is required.
  • Strong SAP knowledge and experience supporting Manufacturing, Supply Chain, and Procurement processes within integrated enterprise environments is required.
  • Experience analyzing process and operational data to identify opportunities, derive actionable insights, and support business decision-making is required.
  • Proven experience translating business requirements into sustainable process solutions and driving implementation in collaboration with business and IT stakeholders is required.
  • Strong understanding of process improvement methodologies and their application in complex organizational environments is required.
  • Stakeholder management, communication, and consulting skills to engage effectively across organizational levels are required.
  • Strong analytical and problem-solving capabilities, combined with a proactive, hands-on, and solution-oriented mindset, are required.
  • Curiosity, drive, and confidence to challenge existing processes while fostering a culture of continuous improvement are required.
  • Fluency in English and Spanish is required.
Responsibilities
  • Analyze, optimize, and further develop end-to-end business processes, focusing on Manufacturing and considering interfaces across Supply Chain and Procurement.
  • Collaborate with business stakeholders to identify process inefficiencies, challenge existing ways of working, and implement sustainable improvements.
  • Drive process excellence initiatives that enhance operational efficiency, process transparency, and business performance across the organization.
  • Use process and operational data to identify improvement opportunities, measure performance, and support data-driven decision-making.
  • Translate business requirements into scalable process solutions and support implementation in collaboration with IT and functional teams.
  • Define, document, and maintain process standards, methodologies, and governance principles to ensure consistency, transparency, and long-term sustainability.
  • Support integration of process- and data-related requirements across systems and functions to enable efficient business operations.
  • Manage process improvement initiatives by coordinating timelines, stakeholders, resources, and deliverables to ensure successful outcomes.
  • Promote knowledge sharing, best practices, and continuous improvement across functions and regions.
  • Contribute hands-on to operational process initiatives while driving long-term process development and business transformation.

About the company

Sartorius provides laboratory and bioprocessing equipment and services for the biopharmaceutical industry. Its two divisions, Bioprocess Solutions and Lab Products & Services, supply systems, consumables, and analytics used in biotech drug and vaccine development and production. It differentiates itself with a long history, an integrated portfolio, global support, and acquisitions like BioOutsource to offer end-to-end solutions. Its goal is to help biopharmaceutical companies develop and manufacture biotech products more reliably and at scale.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Göttingen, Germany

Founded

1870

Get referred to Sartorius

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • H1 2026 operational sales rose 7.7%, and management reaffirmed full-year guidance.
  • May 2026 bond refinancing lowered funding pressure before the €650 million maturity.
  • ElevateBio pilot validation and September 2026 ordering support Eveo sales conversion in 2027.

What critics are saying

  • Tariff refunds and customer compensation cut 2026 revenue by up to €35 million.
  • Lab Products grew only 5.3% operationally in H1 2026, lagging Bioprocess Solutions.
  • Delayed advanced-therapy orders from two customers shift revenue into 2027, hurting execution confidence.

What makes Sartorius unique

  • Eveo launches March 16, 2026, integrating cell therapy manufacturing and QC in one system.
  • Bioprocess Solutions dominates with high-recurring consumables and switching costs across biologics manufacturing.
  • Stedim Biotech integration gives Sartorius tighter control over single-use bioprocessing and global customer relationships.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Flexible Work Hours
  • Wellness Program
  • Professional Development Budget

Company News

Yahoo Finance
Oct 23rd, 2026
Sartorius Stedim Biotech nine-month sales up 7.8% to $2.5B, full-year guidance confirmed

Sartorius Stedim Biotech reported nine-month sales growth of 7.8% in constant currencies, or 6.5% after tariff-related customer compensation. Sales reached €2.29 billion, driven by strong consumables and a recovering equipment business. Underlying EBITDA rose 4.8% to €716 million, with a margin of 31.3%. Underlying net profit climbed 9.4% to €350 million, and free cash flow jumped 58.5% to €264 million. Net debt stood at €2.14 billion, or 2.26 times underlying EBITDA. Americas growth lagged at 3.9% including tariff compensation, hurt by project delays in Advanced Therapies. The company confirmed full-year guidance: operational sales growth near the midpoint of 6% to 10% and an underlying EBITDA margin slightly above 31%.

Yahoo Finance
Jul 23rd, 2026
Sartorius reports 7.7% sales growth as bioprocess equipment stabilises

Sartorius reported solid first-half results, with constant-currency sales up 7.7% and underlying EBITDA rising 3.9% as margins improved to 30.3%. Management confirmed full-year guidance. Bioprocess Solutions led performance, growing 8.3% in constant currencies. Consumables drove growth, whilst equipment stabilised slightly. Chief executive Michael Grosse said demand for biologics remains robust, particularly in monoclonal antibody manufacturing. However, advanced-therapy orders from two customers were delayed and could shift revenue into 2027. Tariff refunds and accounting effects distorted reported results but did not change underlying business trends. The company booked €26 million in customer compensation related to tariffs. Operating cash flow and free cash flow both improved sharply in the first half.

AD HOC NEWS
May 15th, 2026
Sartorius completes full takeover of Stedim Biotech, delisting bioprocessing unit from Euronext Paris

Sartorius Stedim Biotech is set to be delisted from Euronext Paris following a squeeze-out by majority shareholder Sartorius Group. The voluntary tender offer and subsequent acquisition process, which began in early 2024, will transition the company from a separately traded stock into a fully integrated part of Sartorius Group. Headquartered in Aubagne, France, Sartorius Stedim Biotech develops bioprocessing equipment and single-use technologies for biopharmaceutical manufacturing. Its products include bioreactors, filtration systems and process automation tools used by pharmaceutical and biotech companies globally. North America represents a key market, with many US-based biopharma firms using its technologies. The company experienced normalised growth following pandemic-era demand surges, with customers working through elevated inventories accumulated during vaccine production. Despite short-term headwinds, long-term demand drivers remain supported by expanding biologics and advanced therapy pipelines.

wallstreet:online AG
May 6th, 2026
Sartorius completes $560M bond placement with 3.75% coupon to refinance existing debt

Sartorius has completed a €500 million bond placement via its Dutch subsidiary Sartorius Finance B.V. The five-year bond, targeted at institutional investors, was more than four times oversubscribed and carries a 3.75% annual coupon. The life science group will use the proceeds for general corporate purposes, including refinancing existing debt. This includes the redemption of a €650 million bond with a 4.25% interest rate due in autumn 2026. Sartorius has applied for admission to trading on the Euro MTF market of the Luxembourg Stock Exchange. Chief financial officer Florian Funck said the successful issuance strengthens the company's balanced debt maturity profile and long-term financing position, whilst demonstrating investor confidence in Sartorius' strategic direction.

Sartorius
May 6th, 2026
Sartorius completes placement of bond with a volume of 500 million euros

May 6, 2026 – Sartorius has successfully issued a bond with a volume of 500 million euros via its Dutch subsidiary Sartorius Finance B.V.. The issue was targeted at institutional investors and met with strong demand, being more than 4 times oversubscribed.